Outlook Therapeutics, Inc. Human Resources Contracts & Agreements
22 Contracts & Agreements
- Bonus & Incentive Agreements (6 contracts)
- Compensation Agreements (2)
- Consulting Agreements (5)
- Employment Agreements (6)
- Separation Agreements (3)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Equity Incentive Plan (Filed With SEC on August 14, 2024)
- 2024 Equity Incentive Plan (Filed With SEC on August 14, 2024)
- Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy as Amended and Restated, Effective October 1, 2023 (Filed With SEC on December 22, 2023)
- Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective October 1, 2020 (Filed With SEC on December 29, 2022)
- Amended and Restated Executive Employment Agreement by and between Lawrence Kenyon and Outlook Therapeutics, Inc, dated June 2, 2022 (Filed With SEC on June 7, 2022)
- Executive Employment Agreement by and between Jeff Evanson and Outlook Therapeutics, Inc, dated December 21, 2021 (Filed With SEC on December 23, 2021)
- Executive Employment Agreement by and between Terry Dagnon and Outlook Therapeutics, Inc, dated December 21, 2021 (Filed With SEC on December 23, 2021)
- Amendment No. 1 to Consulting Agreement between the Company and The Dagnon Group LLC (Dagnon) dated as of November 8, 2021 (Filed With SEC on November 12, 2021)
- Amendment No.1 to Consulting Agreement between the Company and Scott Three Consulting, LLC (Evanson) dated as of November 8, 2021 (Filed With SEC on November 12, 2021)
- Executive Employment Agreement by and between Lawrence Kenyon and Outlook Therapeutics, Inc, dated July 27, 2021 (Filed With SEC on July 30, 2021)
- Executive Employment Agreement by and between C. Russell Trenary III and Outlook Therapeutics, Inc, dated July 6, 2021 (Filed With SEC on July 9, 2021)
- Consulting Agreement between the Company and Scott Three Consulting, LLC (Evanson), dated as of January 27, 2020 (Filed With SEC on January 31, 2020)
- Consulting Agreement between the Company and The Dagnon Group LLC (Dagnon), dated as of January 27 2020 (Filed With SEC on January 31, 2020)
- Separation and Release Agreement between the Registrant and Kenneth M. Bahrt, M.D., dated April 23, 2019 (Filed With SEC on April 26, 2019)
- Separation Agreement and Release by and between the Registrant and Stephen J. McAndrew, Ph.D., effective as of November 26, 2018 (Filed With SEC on December 18, 2018)
- Executive Employment Agreement between Oncobiologics, Inc. and Lawrence A. Kenyon, dated October 22, 2018 (Filed With SEC on October 26, 2018)
- Consulting Agreement by and between Oncobiologics, Inc. and Pankaj Mohan, Ph.D., dated July 2, 2018 (Filed With SEC on August 14, 2018)
- Separation Agreement and Release by and between Oncobiologics, Inc. and Pankaj Mohan, Ph.D., dated July 2, 2018 (Filed With SEC on August 14, 2018)
- Amended and Restated Performance StockUnit Agreement (Filed With SEC on April 27, 2016)
- Oncobiologics,Inc. 2015 Equity Incentive Plan StockOption Grant Notice (Filed With SEC on January 15, 2016)
- Oncobiologics,Inc. 2015Equity Incentive Plan Adoptedby the Board of Directors: December 4, 2015 Approvedby the Stockholders: December 7, 2015 EffectiveDate: December 4, 2015 (Filed With SEC on January 15, 2016)
- Oncobiologics Inc STOCK INCENTIVE PLAN ArticleI ESTABLISHMENT AND PURPOSES (Filed With SEC on January 15, 2016)
